Abstract
A woman with psoriasis vulgaris and psoriatic arthritis developed granulomatous rosacea after four weeks of therapy with etanercept. When this agent was stopped, her skin lesions rapidly resolved with topical therapy, suggesting a causal relationship between the skin lesions and drug intake. To the best of our knowledge, this is the first report on rosacea as granulomatous cutaneous adverse drug reaction caused by etanercept. No relapse of skin changes appeared under extended and successful anti-psoriatic therapy with infliximab.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antibodies, Monoclonal / administration & dosage*
-
Dermatologic Agents / administration & dosage
-
Dermatologic Agents / adverse effects
-
Etanercept
-
Female
-
Humans
-
Immunoglobulin G / adverse effects*
-
Immunoglobulin G / therapeutic use*
-
Infliximab
-
Psoriasis / complications
-
Psoriasis / drug therapy*
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Rosacea / chemically induced*
-
Rosacea / prevention & control*
-
Secondary Prevention
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Monoclonal
-
Dermatologic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Infliximab
-
Etanercept